Banzel (rufinamide) is a prescription drug used to treat seizures linked to Lennox-Gastaut syndrome. Banzel can cause side effects that range from mild to serious. Examples include sleepiness, ...

Banzel (rufinamide) is a brand-name drug that’s prescribed for treating Lennox-Gastaut Syndrome. Banzel has interactions with alcohol and some other drugs. Examples include opioids and hormone-based ...

Banzel (rufinamide) is a brand-name drug prescribed for certain seizures. Banzel is available as an oral tablet and oral suspension. The cost of Banzel, with and without insurance, can depend on ...

BANZEL has been shown to reduce the QT interval. Caution should be used when administering BANZEL with other drugs that shorten the QT interval. All medications to treat seizures, including BANZEL, ...

Eisai announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Banzel (rufinamide) as adjunctive treatment of seizures associated with ...

Generic Banzel is used for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children aged 4 years old and older and adults. Lupin is introducing Rufinamide Oral ...

Generic Banzel is a prescription add-on medication approved for the treatment of seizures associated with Lennox-Gastaut syndrome in pediatric patients 1 year of age and older and in adults. The Food ...

Rufinamide 40mg/mL; orange-flavor; lactose-, gluten-, and dye-free. The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest ...

Japan’s Eisai Corp has been boosted by the news that regulators in the USA have given the green light to Banzel for the treatment of epilepsy. Japan’s Eisai Corp has been boosted by the news that ...

The newly launched drug is a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai, Inc. Banzel tablets are used in combination with other medications to treat children with ...

New Treatment Option for Seizures Associated with Lennox-Gastaut Syndrome WOODCLIFF LAKE, N.J., Nov. 14 /PRNewswire/ -- Eisai Corporation of North America announced today that the U.S. Food and Drug ...

Pfizer’s Lyrica is the leader in the anti-epileptic drugs market. Epilepsy is a condition in which a person has recurrent seizures. Other approved anti-epileptic drugs include UCB’s Keppra and Vimpat, ...